Our corporate responsibility program
At Ultragenyx, our corporate responsibility strategy helps us identify, manage and communicate on topics relevant to our business and stakeholders and is structured around six key pillars:
- Innovation
- Patients
- People
- Communities
- Planet
- Governance
By focusing on these pillars, we strive to make a meaningful difference in the lives of those affected by rare and ultra-rare diseases.
To learn more about our corporate responsibility priorities,download the Materiality Assessment
Our 2025 Impact Report
Our 2025 Impact Report covers our approach to corporate responsibility and highlights our ongoing commitment to transparency.
The report details our:
- Innovative approach to drug development
- Efforts towards providing equitable access to our medicines and improved care for people impacted by the rare diseases we study
- Commitment to creating an inclusive workplace culture
- Philanthropic support for community initiatives
- Efforts to reduce our environmental footprint
- Emphasis on strong corporate governance and a culture of integrity
Our strategic pillars
Commitment
We are a next-generation rare disease company committed to developing and delivering transformative treatments where none typically exist.
participants representing more than 140 organizations have attended our Rare BootcampTM since 2017.
locations with clinical studies across 19 countries as of Dec. 31, 2025.
of operating expenses were spent on R&D in 2025.
Commitment
We are committed to supporting the rare disease community through our efforts to develop novel therapies, share our science and expertise, achieve broad access to screening and treatment, and partner with policymakers for meaningful change.
patients in 50 countries have been approved for access to Ultragenyx treatments through various global expanded access and patient assistance programs since 2013.
patient advocacy conferences, meetings and town halls attended worldwide in 2025.
global listen and learn sessions convened with rare disease communities to collect actionable feedback and inform strategies across 8 programs.
Commitment
We are committed to working to maintain an inclusive, safe and healthy environment. We are also committed to fair and equitable compensation practices that are transparent and free from bias.
employee learning & development workshops in 2025.
employee engagement score in 2025.*
students hosted across our Emerging Talent programs in 2025.
*A subset of the employee engagement survey—focused on employee pride in our company, whether an employee would recommend Ultragenyx as a good place to work, whether an employee experiences a feeling of personal accomplishment from their work and the employee’s intent to remain with us—is used to calculate an employee engagement score.
Commitment
We are committed to supporting initiatives that provide meaningful impact for the rare disease community, public health and access to care, Science, Technology, Engineering, Arts and Mathematics (STEAM) education, and local, at-risk communities.
in charitable donations, independent medical education and health-related grants across more than 20 countries approved in 2025.
volunteer hours recorded by eligible employees in 2025.
service projects hosted around the world during our 3rd annual Days of Service in 2025.
Commitment
We are committed to implementing an environmental strategy that helps to minimize our environmental footprint across our business.
renewable electricity procured at our Novato, CA headquarters and Bedford, MA gene therapy manufacturing facility.
pounds of laboratory waste diverted from incineration in 2025 through our recycling partnerships.
Climate Risk Assessment completed to identify actual and potential impacts of climate-related risks and opportunities in our business.
Commitment
The foundation of our purpose to lead the future of rare disease medicine is built upon our commitments to strong corporate governance, ethics and integrity, compliance, data protection and security and responsible procurement.
requirements for our directors and named executive officers.
material data privacy breaches or known security breaches or incidents resulting in material impact to our operations in 2025.
Resources
Awards and recognitions
Discover more about Ultragenyx:
Grants and contributions
Ultragenyx supports initiatives that provide impactful resources for the rare disease community.
View grants and charitable contributions